ESMO 2026

lidERA - quality of life

NATALEE at 6 Years: Survival Benefit Confirmed

From Japan to Germany: ctDNA results and their…

Two drugs with durable benefit improve outcomes in…

Ribociclib still lowers recurrence risk after 6 years

NATALEE a 6 anni: confermato il beneficio in termini di…

O ribociclib continua a reduzir o risco de recidiva…

Leptomeningeal metastases: new hope with intrathecal…

CDK4/6 Rechallenge or New Strategies? The…

Brain mets: are ADCs changing the rules?

A positive trial – but is it practice-changing?

Anbenitamab in HER2+ BC

Can a PET scan predict hormone therapy response?

Anbenitamab: Longer Disease Control in HER2+ Breast…

Brain mets in TNBC

Can a PET Scan Predict Treatment Response in Breast…

Updated results of VIKTORIA-1

Does adding immunotherapy to chemo help?

T-DXd + Pertuzumab shows impressive intracranial…

CTCs in DETECT V: potential role in therapeutic…

Subgroup analysis of ASCENT-04

Expanding therapeutic options for patients with HR+ mBC

What helps when CDK4/6 therapy stops working?

Brain mets in HER2+

Atirmociclib after CDK4/6i

Not a new question, but compelling data: Immunotherapy…

Dato-DXd and brain metastases

Functional imaging defines a new class of luminal mBC

Triple-negative breast cancer: does the new therapy…

Trastuzumab rezetecan for HER2 low mBC

Dato-DXd Benefit Extends to Brain Metastases

Biparatopic antibody

Dato-DXd for patients with brain mets

Significant impact in OS favoring Sac-TMT in aBC

Atirmociclib: A New Option After CDK4/6 Failure

CDK4 inhibition with atirmociclib

Important opportunities for patients with TNBC and…

Intrathecal Trastuzumab/Pertuzumab shows impressive…

L'imaging funzionale identifica una nuova categoria di…

Anbenitamab: dłuższe opanowanie choroby w przypadku…

הרחבת האפשרויות הטיפוליות לחולים עם סרטן שד גרורתי…

I benefici di Dato-DXd si estendono alle metastasi…

Dato-DXd per pazienti con metastasi cerebrali

El tratamiento con T-DXd + pertuzumab muestra una…

הזדמנויות חשובות לחולים עם סרטן שד שלילי ל-TNBC וגרורות…

El estudio BRIDGET demuestra que la incorporación del…

El tratamiento intratecal con trastuzumab y pertuzumab…

Impacto significativo en la supervivencia global a…

Atirmociclib: una nuova opzione dopo il fallimento…

Czy badanie PET pozwala przewidzieć odpowiedź na…

Résultats actualisés de l'étude VIKTORIA-1

Trastuzumab rezetecan per il carcinoma mammario…

Análise por subgrupos do estudo ASCENT-04

Anbenitamab nel carcinoma mammario HER2-positivo

Improvement of pCR for PD-L1 0%

pCR-Prediction

Osimertinib + savolitinib redefines post-osi treatment

Sac-TMT as a new 1L option for PD-L1-non-expressing…

PERSEE challenges pembrolizumab monotherapy in…

Transformation of KRAS G12C-mutated NSCLC

OMD - radiotherapy yes or no?

Immune therapy - limitation and intensification

Sac-TMT is the first ADC + pembrolizumab to demonstrate…

Sac-TMT redefines first-line treatment in…

Targeting MET in EGFR - biomarker selection or not?

Molecular selection of patients after osimertinib…

Divarasib - a game changer for KRAS G12C-mutated mNSCLC

NSCLC - 2nd line journey is going on

Is local radical therapy dead for synchronous…

DESTINY-Lung04: Quality of Life with T-DXd in…

Divarasib beats sotorasib/adagrasib

MET in EGFRm NSCLC

Intensification of therapy in PD-L1-high NSCLC patients

New kids on the block, don't forget to test

New ADC data in 2L EGFR-mutated NSCLC

Divarasib challenges firstgeneration inhibitors in KRAS…

Redefinition of SOC in PD-L1-high advanced NSCLC

Do we need chemotherapy in high PD-L1?

TROP2-ADC - what´s next?

Is lokale radicale therapie niet langer een optie bij…

Sélection moléculaire des patients après échec de…

Nuovi arrivati sulla scena – non dimenticate di testare

Sac-TMT est le premier ADC + pembrolizumab à démontrer…

Divarasib - un tournant majeur dans le CBNPC…

Intensification du traitement chez les patients…

Redéfinition du standard de soins dans le CBNPC avancé…

Divarasib presteert beter dan sotorasib/adagrasib

New SOC in 1L maintenance therapy in ES-SCLC

Tarlatamab - new SOC in maintenance therapy

After 50 years, the greatest improvement in SCLC…

Tarlatamab moves to the 1L

Tarlatamab changes SOC in ES-SCLC

Mind-blowing study in ES-SCLC

Tarlatamab confirma un beneficio duradero en…

Après 50 ans, la plus grande avancée dans le traitement…

Tarlatamab – nieuwe SOC bij onderhoudsbehandeling

Nouveau standard de soins en traitement d’entretien de…

Rethinking Second-Line Treatment in RCC

Why Triplets Failed in First-Line RCC

Bispecifics and CAR-T in RCC: The Next Breakthrough?

Doublets or triplets for RCC?

Is triplet better than doublet?

A New Approach to Rare Renal Cancers

Latest Developments and Outlook: 1st-line mRCC

KEYNOTE-564 Final Analysis: Adjuvant Pembrolizumab in…

Quality of life with adjuvant durvalumab

Final analysis of lenvatinib in metastatic RCC

Doublet or singlet in 2nd line?

Lenvatinib + Belzutifan do not meet the OS-expectations…

Triplets fail to outperform doublets

Bispecific antibodies in RCC

Treatment after immunotherapy in advanced RCC: CARAT…

Lenvatinib + belzutifan show response in PFS but not OS

ADC-based strategies in mUC: what's next?

VOLGA: a new perioperative standard in MIBC?

Muscleinvasive: VOLGA!

Clearance of ctDNA

Triple Combo SG + EV + ZIM in First-Line Bladder Cancer

New hope in advanced urothelial carcinoma

Lack of consistency in the perioperative setting: What…

Perioperative immunotherapy in MIBC

Less treatment, better outcomes?

Bladder cancer highlights from ESMO 2026

What's up in UTUC: WUTSUP-02

Is triplet therapy the next step for 1L treatment in…

Σημαντικότερα νέα στον καρκίνο της ουροδόχου κύστης από…

Falta de consistencia en el tratamiento perioperatorio:…

Is Surgery Alone Still Enough for High-Risk Prostate…

A New Standard for High-Risk Prostate Cancer?

Long-Term Survival Gains – But Is Docetaxel Really…

RIPTAC: The Next Big Breakthrough in Prostate Cancer?

PTEN emerges as a biomarker

Long term follow-up of PEACE-1: The value of time in…

A new era for high-risk prostate cancer?

Update of CAPItello-281

Clonal hematopoiesis and PARP-inhibition

PROTEUS substudy: perioperative intensification in…

JNJ-6143 in mCRPC: First RIPTAC Shows Strong Early…

8-year follow-up reinforces the case for triplet…

PROTEUS Substudy: Apalutamide Before and After…

Treatment intensification matters, but so does…

Escalation with darolutamide in very high-risk patients

Long term follow-up of CAPItello-281: The value of time…

RIPTAC - new way to target the androgen receptor

PEACE-1: El valor del tiempo en el cáncer de próstata…

Uppdatering av CAPItello-281

La intensificación del tratamiento importa, pero…

Förvärrad sjukdom hos patienter med mycket hög risk som…

RIPTAC – ett nytt sätt att påverka androgenreceptorn

Klonal hematopoies och PARP-hämning

We are too slow

A new treatment for thymic carcinoma

Updates on Soft Tissue Tumors

Claudin-6: Is this the new target to follow in germ…

R/M HNSCC new mode of actions!?

Neoadjuvant Toripalimab Plus TIP in Locally Advanced…

Ixotatug vedotin in germ cell tumors